Video Talk:Psoriasis
PASI score
PASI stands for Psoriasis Area and Severity Index. PASI includes the amount of body surface area that is affected by psoriasis in addition to three major symptoms: redness, inflammation, and the thickness of the scale on the skin. A patient is given a PASI score from 0-72 where 0 means no psoriasis and 72 means the most severe psoriasis. A PASI score is given to a patient before treatment and then after treatment to determine the effectiveness of the therapy. The goal of successful psoriasis treatment is to reduce the PASI score as close to 0 (no psoriasis) as possible.
Maps Talk:Psoriasis
Ultraviolet info seems self-contradictory
Ultraviolet wavelengths are subdivided into UVA (380-315 nm), UVB (315-280 nm), and UVC (< 280 nm). Ultraviolet B (UVB) (315-280 nm) is absorbed by the epidermis and has a beneficial effect on psoriasis. Narrowband UVB (311 to 312 nm), is that part of the UVB spectrum that is most helpful for psoriasis.
Query: If UVA is from 380-315 nm, it includes 311-312 nm. So how come Narrowband UV (311 to 312 nm) is supposed to be UVB instead of UVA?
- Answer: 380-315nm does not included 311-312nm. 311-312 is less than 315.
Vitamin D therapy in psoriasis.
Araugo OE, Flowers FP, Brown K.
Vitamin D therapy in psoriasis.
DICP. 1991 Jul-Aug;25(7-8):835-9. Review.
PMID 1659041
- Abstract : The use of vitamin D3 in the treatment of psoriasis is discussed with emphasis on positive and negative results of many clinical trials. Investigations indicate the treatment with topical vitamin D3 provides consistently more rapid clinical improvement than its oral counterpart, with no reported adverse effects. Studies have shown that 68 of 83 patients exhibited significant improvement of their psoriatic lesions with the topical application of vitamin D3 analogs, including 1,24-dihydroxycholecalciferol, calcitriol, and MC 903. Clinical trials involving 35 patients treated with oral vitamin D3 analogs resulted in moderate improvement in 24 of the patients. Adverse effects can be minimized by bedtime dosing and possibly the use of new noncalciotropic analogs. Vitamin D3 analogs appear to provide one more promising treatment option for psoriasis.
Morimoto S, Yoshikawa K.
Psoriasis and vitamin D3. A review of our experience.
Arch Dermatol. 1989 Feb;125(2):231-4.
Abstract
Psoriasis is associated with abnormally exaggerated epidermal cellular turnover. Recent studies showed that calcitriol (1,25-dihydroxyvitamin D3) a calcitrophic hormone, regulates terminal differentiation of basal cells of epidermal keratinocytes. We administered active forms of vitamin D3 in both oral and topical ways in an open-design study to patients with psoriasis vulgaris. Significant improvement was observed at the end of the study periods in these patients, especially in those treated with topical application of calcitriol. We also found a significant negative correlation between the severity of psoriasis and the basal serum level of 1 alpha,25-dihydroxyvitamin D but not with those of other calcium-related parameters in psoriatic patients. These data suggest that exogenous active forms of vitamin D3 are effective for treatment of psoriasis and that the endogenous 1,25-dihydroxyvitamin D level also may be involved in the development of this skin disease.
PMID 2536537
Kamangar F, Koo J, Heller M, Lee E, Bhutani T.
Oral vitamin D, still a viable treatment option for psoriasis.
J Dermatolog Treat. 2012 Jan 21. [Epub ahead of print]
PMID 22103655
- Abstract : Vitamin D as a topical treatment has become one of the mainstays for treatment of psoriasis vulgaris. Oral vitamin D on the other hand has for the most part become a forgotten option. But a review of the literature on oral vitamin D as a treatment for psoriasis reveals that this treatment is efficacious. The main side effect of this therapy is hypercalcemia, which appears to be easily monitored and avoidable with proper dosing and monitoring. The literature also suggests a correlation between low levels of serum vitamin D in this patient population associated with increased severity of disease involvement. In addition, oral vitamin D improves psoriatic arthropathy. Moreover, vitamin D has been proven to have many health benefits such as prevention of cancer, improved cardiovascular health among many others. Psoriatic patients as a population are at increased risk of developing adverse health complications such as cardiovascular disease, and oral vitamin D may prove to be of benefit in this population. Oral vitamin D is inexpensive and easily available. It is still a viable option and should not be forgotten as a possible treatment for psoriasis.
Grace K. Kim, DO
The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis; Where Does Topical Calcitriol Fit In?
J Clin Aesthet Dermatol. 2010 August; 3(8): 46-53.
PMCID PMC2945865
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945865/ </ref>
- "The therapeutic use of vitamin D dates back to the 1930s when it was used as an oral agent for osteoporosis on a psoriasis patient who subsequently experienced clearing of psoriatic skin lesions.10 Dermatological application of topical vitamin D3 centers on the fact that the skin is both a site of initial vitamin D biosynthesis and a target for vitamin D3 activity causing modulation of keratinocytes and inflammatory mediators.11" [1]
Cites in above block quote:
10: Nagpal S, Lu J, Boehm MF
Review Vitamin D analogs: mechanism of action and therapeutic applications.
Curr Med Chem. 2001 Nov; 8(13):1661-79.
PMID 11562285
11: Wolverton SE.
Comprehensive Dermatologic Drug Therapy. 2nd Edition.
Philadephia, PA: Saunders Elsevier; 2007.
- Interesting that the first 3 references above mention experience with oral vitamin D - Should cover in article ? - Rod57 (talk) 11:27, 20 July 2017 (UTC)
Mention the generic (calcitriol) along with the patented (calcipotriol)?
Moisturizers and emollients such as mineral oil, petroleum jelly, calcipotriol or calcitriol, and decubal (an oil-in-water emollient) were found to increase the clearance of psoriatic plaques. Emollients have been shown to be even more effective at clearing psoriatic plaques when combined with phototherapy. However, certain emollients have no impact on psoriasis plaque clearance or may even decrease the clearance achieved with phototherapy. The emollient salicylic acid is structurally similar to para-aminobenzoic acid (PABA), commonly found in sunscreen, and is known to interfere with phototherapy in psoriasis. Coconut oil, when used as an emollient in psoriasis, has been found to decrease plaque clearance with phototherapy. Medicated creams and ointments applied directly to psoriatic plaques can help reduce inflammation, remove built-up scale, reduce skin turnover, and clear affected skin of plaques. Ointment and creams containing coal tar, dithranol, corticosteroids (i.e. desoximetasone), fluocinonide, vitamin D3 analogs (for example, calcipotriol or calcitriol), and retinoids are routinely used. The use of the finger tip unit may be helpful in guiding how much topical treatment to use.
References
Proposed role of Rac1
A paper published here in JCI, and reported by Stanford University here suggests a role for Rac1 in psoriasis; I don't know enough to add this to the article, but it looks to merit a mention both here and under Rac1. Hv (talk) 09:17, 15 July 2017 (UTC)
how to cure -- Preceding unsigned comment added by 117.227.38.205 (talk) 17:44, 9 March 2018 (UTC)
Source of the article : Wikipedia
0 Comments